Want to see TSE:RX full AI Analyst Report?
Top Page
Biosyent
(RX)
Select Model
Select Model
Rating:86Outperform
Price Target:
C$20.50
▲(30.57% Upside)
Action:Reiterated
Date:08/22/26
The score is driven primarily by strong financial performance—fast revenue growth, high margins, and an exceptionally conservative balance sheet—partly tempered by less consistent recent cash-flow conversion. Technicals add support with a clear uptrend and positive momentum indicators. Valuation is reasonable with a moderate P/E and modest dividend yield.
Positive Factors
Strong revenue growth and profitability
TTM revenue reached $55.7M, up 21.1%, extending a multi-year upward trend. Combined with ~70% gross margin, ~23.6% EBIT margin and ~17.7% net margin, this indicates strong product economics and creates room to fund commercialization and portfolio expansion.
Negative Factors
Margin compression
Although profitability remains strong, lower gross and net margins versus prior years indicate that earnings quality is facing some pressure as the business scales. If sustained, this compression could reduce the amount of revenue growth that converts into operating and net profit.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth and profitability
TTM revenue reached $55.7M, up 21.1%, extending a multi-year upward trend. Combined with ~70% gross margin, ~23.6% EBIT margin and ~17.7% net margin, this indicates strong product economics and creates room to fund commercialization and portfolio expansion.
Read all positive factors
Biosyent (RX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$193.95M
Dividend Yield1.25%
Average Volume (3M)7.43K
Price to Earnings (P/E)19.5
Beta (1Y)0.84
Revenue Growth40.91%
EPS Growth19.88%
CountryCA
Employees60
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.88
Shares Outstanding11,308,835
10 Day Avg. Volume2,232
30 Day Avg. Volume7,427
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.46
Price to Sales (P/S)3.33
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$18.00Price Target Upside14.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.89
Revenue Forecast (FY)C$69.00M
Biosyent Business Overview & Revenue Model
Company Description
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficien...
How the Company Makes Money
Biosyent makes money primarily by commercializing healthcare products in Canada that it acquires or in-licenses from other product owners (e.g., pharmaceutical or healthcare companies) and then markets, sells, and distributes under agreed rights. ...
Biosyent Earnings Call Summary
Earnings Call Date:Aug 21, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue and profit growth across various business segments, consistent profitability, and successful dividend and share buyback programs. However, some product lines underperformed, and trade uncertainties remain a concern. Despite these challenges, the overall performance and growth initiatives present a positive outlook.Positive Updates
Strong Revenue Growth
Total company revenue was just over $10 million, representing a 14% growth compared to the previous year, with Canadian Pharma having a record quarter.
Negative Updates
Combogesic Performance Lag
Combogesic has been underperforming and lagging behind expectations for some time.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Revenue Growth
Total company revenue was just over $10 million, representing a 14% growth compared to the previous year, with Canadian Pharma having a record quarter.
Read all positive updates
Company Guidance
During the BioSyent Inc. Q2 and First Half 2025 Results Presentation, President and CEO René C. Goehrum highlighted strong financial performance with total company revenue just over $10 million for the quarter, reflecting a 14% growth compared to the previous year. Canadian Pharma achieved a record quarter with sales of $9.3 million, a 9% year-over-year increase. The company's EBITDA reached just under $2.8 million, growing by 35%, and NIAT exceeded $2 million, up 28% from the previous year, with EBITDA and NIAT margins at 27% and 20%, respectively. On a six-month basis, sales rose by 27% to over $21 million, driven by growth across Canadian Pharmaceutical, International Pharma, and Legacy business segments. EBITDA increased by 40% to nearly $6 million, while NIAT grew by 30% to over $4.3 million, with corresponding margins of 28% and 21%. The presentation also noted an EPS of $0.18 for Q2 2025, contributing to a trailing-12 month EPS of $0.72. BioSyent continued its share buyback program, repurchasing 19,500 shares year-to-date, and declared a dividend of $0.05 for September, marking an 11% increase over the previous year's dividend. The company maintained a strong cash position with $27 million as of June 30, 2025, and reported a 23% return on equity.Biosyent Financial Statement Overview
Summary
Income Statement
90
Very Positive
Balance Sheet
95
Very Positive
Cash Flow
83
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 55.67M | 43.05M | 35.03M | 31.59M | 27.93M | 28.62M |
| Gross Profit | 39.09M | 32.11M | 27.86M | 25.60M | 22.86M | 22.64M |
| EBITDA | 15.12M | 12.17M | 10.43M | 9.06M | 7.43M | 8.64M |
| Net Income | 9.87M | 9.01M | 7.27M | 6.46M | 5.46M | 6.28M |
Balance Sheet | ||||||
| Total Assets | 60.46M | 49.44M | 41.36M | 41.53M | 40.49M | 37.17M |
| Cash, Cash Equivalents and Short-Term Investments | 8.94M | 28.65M | 15.94M | 26.19M | 28.70M | 28.21M |
| Total Debt | 3.14M | 841.10K | 1.04M | 1.22M | 1.40M | 1.56M |
| Total Liabilities | 14.62M | 7.97M | 6.36M | 6.77M | 7.12M | 5.61M |
| Stockholders Equity | 45.84M | 41.47M | 35.00M | 34.76M | 33.36M | 31.55M |
Cash Flow | ||||||
| Free Cash Flow | 11.80M | 9.57M | 3.99M | 4.88M | 4.43M | 4.58M |
| Operating Cash Flow | 12.09M | 9.62M | 8.66M | 5.05M | 4.95M | 4.67M |
| Investing Cash Flow | -16.18M | 3.48M | 3.29M | 883.85K | -10.79M | -4.84M |
| Financing Cash Flow | -4.20M | -3.41M | -7.83M | -5.78M | -4.37M | -2.08M |
Biosyent Technical Analysis
Positive
15.70
Price Trends
15.81
Positive
14.99
Positive
14.59
Positive
Market Momentum
0.34
Negative
63.48
Neutral
92.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RX, the sentiment is Positive. The current price of 15.7 is below the 20-day moving average (MA) of 16.53, below the 50-day MA of 15.81, and above the 200-day MA of 14.59, indicating a bullish trend. The MACD of 0.34 indicates Negative momentum. The RSI at 63.48 is Neutral, neither overbought nor oversold. The STOCH value of 92.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RX.
Biosyent Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | C$193.95M | 19.49 | 22.92% | 1.25% | 40.91% | 19.88% | |
63 Neutral | C$155.56M | -45.43 | -4.69% | ― | -3.16% | -345.50% | |
58 Neutral | C$126.52M | -10.35 | -14.43% | 3.42% | -1.18% | 42.93% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | C$214.78M | -5.17 | -180.13% | ― | ― | 29.34% | |
42 Neutral | C$60.61M | -0.76 | -2099.75% | ― | -100.00% | 94.43% | |
38 Underperform | C$663.17K | 3.13 | -2.92% | ― | ― | ― |
* General Sector Average
TSE:RX
Biosyent
17.15
5.77
50.76%
TSE:AQS
Aequus Pharmaceuticals
0.01
0.00
0.00%
TSE:ATLE
Willow Biosciences Inc
0.13
-0.05
-27.78%
TSE:MDP
Medexus Pharmaceuticals Inc
4.95
2.16
77.42%
TSE:HLS
HLS Therapeutics Inc
4.09
-1.43
-25.91%
TSE:CRDL
Cardiol Therapeutics
1.78
0.32
21.92%
Biosyent Corporate Events
Business Operations and StrategyFinancial Disclosures
BioSyent Earns Spot on Canada’s Top Growing Companies 2026 List
Positive
Sep 25, 2026
BioSyent Inc., a TSX Venture-listed specialty healthcare firm, focuses on in-licensed and acquired pharmaceutical and oral health products that improve patient outcomes. Operating in Canada and abroad, the company markets these therapies to health...
Business Operations and StrategyDividends
BioSyent Maintains Quarterly Dividend as Specialty Healthcare Growth Continues
Positive
Aug 20, 2026
BioSyent Inc., a specialty healthcare company listed on the TSX Venture Exchange, markets and distributes innovative pharmaceutical and oral health products in Canada and abroad, targeting therapies that improve patient outcomes. With a profitable...
Business Operations and StrategyStock BuybackDividendsFinancial Disclosures
BioSyent’s New Oral Health Segment Powers Surging Q2 2026 Earnings
Positive
Aug 20, 2026
BioSyent reported a sharp expansion in Q2 and H1 2026 results, driven largely by the first full quarter contribution from its newly acquired Oral Health segment. Total company sales nearly doubled year-over-year in Q2 to $19.9 million, with pharma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.